Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone-metformin and liraglutide for type 2 diabetes mellitus with metabolic associated fatty liver disease
ChiCTR2200060695Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Nov 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of pioglitazone, metformin and liraglutide in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Intrahepatic lipid content. Started Nov 2021; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2200060695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060695.